TITLE

FURTHER READING

PUB. DATE
November 2011
SOURCE
PharmaWatch: CNS;Nov2011, Vol. 10 Issue 11, p27
SOURCE TYPE
Market Research Report
DOC. TYPE
Article
ABSTRACT
The article lists the latest reports in the U.S. pharmaceutical industry which include drugs for the treatment of Scizophrenia, overview of neuropathic pain definitions in HIV, diabetes, and herpes zoster, and company profile of UCB SA.
ACCESSION #
67505027

 

Related Articles

  • Busy Schizophrenia Market, But Alkermes Presses On. Orelli, Brian // BioWorld Insight;1/3/2012, Vol. 20 Issue 1, p2 

    The article reports on the stiff competition among pharmaceutical industries in the U.S. in giving treatment alternatives for schizophrenia in the U.S. It highlights the move of Alkermes PLC in starting its phase III trial in relation to its ALKS 9070. It adds that aside from fast-acting oral...

  • Pipeline.  // Pharmaceutical Representative;Jan2010, Vol. 40 Issue 1, p10 

    The article reports developments in the pharmaceutical industry in the U.S. Phase III study that evaluates ocrelizumab in patients with rheumatoid arthritis from Roche Holding AG reveals its primary efficacy endpoints. Findings about Vimbat, an antiepileptic drug from UCB SA, show clinical...

  • UCB makes R&D investment.  // Chemical Week;8/7/1996, Vol. 158 Issue 30, p6 

    Reports on UCB's investment in a research and administrative center in Brussels, Belgium.

  • ABOUT UCB.  // Worldwide Biotech;Aug2011, Vol. 23 Issue 8, p6 

    The article provides information on UCB, a biopharmaceutical firm based in Brussels, Belgium, with over 8,000 employees in 40 countries, and is listed on the Euronext Brussels under the UCB symbol.

  • UCB-Bioproducts.  // BioPharm International;Dec2001, Vol. 14 Issue 12, p86 

    Focuses on the corporate capabilities of UCB-Bioproducts in Georgia. Company profile; Services offered; Marketing strategies.

  • UCB plans jv resins plant in Shanghai.  // Chemical Market Reporter;11/16/98, Vol. 254 Issue 20, p28 

    Reports on UCB SA's plan to construct a chemical plant in Shanghai, China to manufacture Cryloat polyester resins for solvent-free powder paints.

  • Pharma: Other News To Note.  // BioWorld Today;4/3/2013, Vol. 24 Issue 63, p9 

    The article reports that Health Canada approved Neupro (rotigotine) non-ergolinic dopamine agonist in patch form, from UCB SA.

  • VIMPAT.  // Physician Assistants' Prescribing Reference;Fall2009, Vol. 16 Issue 3, pA12 

    The article evaluates the Vimpat (Lacosamide) antiepileptic drugs from UCB Sa.

  • VIMPAT.  // MPR - Residents' Edition;Fall/Winter2009, Vol. 18 Issue 2, pA6 

    The article evaluates the antiepileptic drug Vimpat from UCB SA.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics